{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:20:21Z","timestamp":1787026821605,"version":"build-2736575974"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T00:00:00Z","timestamp":1658102400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Myotonic dystrophy type 2 (DM2) is a rare autosomal dominant multisystemic disease with highly variable clinical presentation. Several case reports and one cohort study suggested a significant association between DM2 and autoimmune diseases (AIDs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>The aim of this study is to analyze the frequency and type of AIDs in patients with DM2 from the Serbian DM registry.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>A total of 131 patients with DM2 from 108 families were included, [62.6% women, mean age at DM2 onset 40.4 (with standard deviation 13) years, age at entering the registry 52 (12.8) years, and age at analysis 58.4 (12.8) years]. Data were obtained from Akhenaten, the Serbian registry for DM, and through the hospital electronic data system.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Upon entering the registry, 35 (26.7%) of the 131 patients with DM2 had AIDs including Hashimoto thyroiditis (18.1%), rheumatoid arthritis, diabetes mellitus type 1, systemic lupus, Sjogren's disease, localized scleroderma, psoriasis, celiac disease, Graves's disease, neuromyelitis optica, myasthenia gravis, and Guillain-Barre syndrome. At the time of data analysis, one additional patient developed new AIDs, so eventually, 36 (28.8%) of 125 DM2 survivors had AIDs. Antinuclear antibodies (ANAs) were found in 14 (10.7%) of 63 tested patients, including 12 without defined corresponding AID (all in low titers, 1:40 to 1:160). Antineutrophil cytoplasmic antibodies (ANCAs) were negative in all 50 tested cases. The percentage of women was significantly higher among patients with AIDs (82.9% vs. 55.2%,\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt;0.01).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>AIDs were present in as high as 30% of the patients with DM2. Thus, screening for AIDs in DM2 seems reasonable. Presence of AIDs and\/or ANAs may lead to under-diagnosis of DM2.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2022.932883","type":"journal-article","created":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T11:36:50Z","timestamp":1658144210000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Autoimmune Diseases in Patients With Myotonic Dystrophy Type 2"],"prefix":"10.3389","volume":"13","author":[{"given":"Stojan","family":"Peric","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelena","family":"Zlatar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luka","family":"Nikolic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vukan","family":"Ivanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jovan","family":"Pesovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Petrovic Djordjevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana","family":"Sreckovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dusanka","family":"Savic-Pavicevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Meola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vidosava","family":"Rakocevic-Stojanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,18]]},"reference":[{"key":"B1","first-page":"222","article-title":"Myotonic dystrophy type 2: the 2020 update","volume":"39","author":"Meola","year":"2020","journal-title":"ActaMyol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.nmd.2021.06.002","article-title":"Cerebral involvement and related aspects in myotonic dystrophy type 2","volume":"31","author":"Peric","year":"2021","journal-title":"NeuromusculDisord"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1007\/s00415-013-6993-0","article-title":"Diagnostic odyssey of patients with myotonic dystrophy","volume":"260","author":"Hilbert","year":"2013","journal-title":"J Neurol."},{"key":"B4","first-page":"1","volume-title":"Myotonic Dystrophy Type 2. GeneReviews","author":"Schoser","year":"2022"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1016\/j.ajpath.2011.07.013","article-title":"RNA Foci, CUGBP1, and ZNF9 are the primary targets of the mutant CUG and CCUG repeats expanded in myotonic dystrophies type 1 and type 2","volume":"179","author":"Jones","year":"2011","journal-title":"Am J Pathol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1212\/01.WNL.0000054481.84978.F9","article-title":"Myotonic dystrophy type 2: molecular, diagnostic and clinical spectrum","volume":"60","author":"Day","year":"2003","journal-title":"Neurology"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1136\/jnnp.2008.156562","article-title":"Strong association between myotonic dystrophy type 2 and autoimmune diseases","volume":"80","author":"Tieleman","year":"2009","journal-title":"J NeurolNeurosurg Psychiatry."},{"key":"B8","doi-asserted-by":"publisher","first-page":"461","DOI":"10.3233\/JND-180328","article-title":"Myotonic dystrophy type 2 - data from the serbian registry","volume":"5","author":"Bozovic","year":"2018","journal-title":"J Neuromuscul Dis."},{"key":"B9","doi-asserted-by":"publisher","first-page":"391821","DOI":"10.1155\/2013\/391821","article-title":"Molecular genetics and genetic testing in myotonic dystrophy type 1","volume":"2013","author":"Savi\u0107-Pavi\u0107evi\u0107","year":"2013","journal-title":"Biomed Res Int"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1007\/s00415-017-8574-0","article-title":"Magnetic resonance imaging of leg muscles in patients with myotonic dystrophies","volume":"264","author":"Peric","year":"2017","journal-title":"J Neurol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/joim.12395","article-title":"Human autoimmune diseases: a comprehensive update","volume":"278","author":"Wang","year":"2015","journal-title":"J Intern Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1007\/s00415-020-10394-5","article-title":"Physical fatigability and muscle pain in patients with Hashimoto thyroiditis","volume":"268","author":"Jordan","year":"2021","journal-title":"J Neurol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1002\/jcsm.12889","article-title":"Immunometabolic signatures predict recovery from thyrotoxic myopathy in patients with Graves' disease","volume":"13","author":"Setoyama","year":"2022","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"B14","doi-asserted-by":"publisher","first-page":"133","DOI":"10.4081\/reumatismo.2018.1051","article-title":"Histopathology of the muscle in rheumatic diseases","volume":"70","author":"Barsotti","year":"2018","journal-title":"Reumatismo."},{"key":"B15","doi-asserted-by":"publisher","first-page":"130","DOI":"10.3988\/jcn.2013.9.2.130","article-title":"The coexistence of myasthenia gravis and myotonic dystrophy type 2 in a single patient","volume":"9","author":"Nikolic","year":"2013","journal-title":"J Clin Neurol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1055\/s-0028-1090103","article-title":"Coincidence of myasthenia gravis and myotonic dystrophy type 2","volume":"39","author":"Bamberg","year":"2008","journal-title":"KlinNeurophysiol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1007\/s10072-011-0782-2","article-title":"Myotonic dystrophy type 2 and autoimmune chronic gastritis: an incidental association?","volume":"32","author":"Sicurelli","year":"2011","journal-title":"Neurological Sci"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1016\/j.clineuro.2012.03.034","article-title":"Myotonic dystrophy type 2 and multiple sclerosis: case report","volume":"114","author":"Ehler","year":"2012","journal-title":"Clin Neurol Neurosurg"},{"key":"B19","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.nmd.2014.09.009","article-title":"Eosinophilic myositis as first manifestation in a patient with type 2 myotonic dystrophy CCTG expansion mutation and rheumatoid arthritis","volume":"25","author":"Meyer","year":"2015","journal-title":"Neuromuscular Disord."},{"key":"B20","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3233\/JND-160192","article-title":"Neuromyelitis Optica in a Patient from Family with both Myotonic Dystrophy Type 1 and 2","volume":"4","author":"Rakocevic-Stojanovic","year":"2017","journal-title":"J Neuromuscular Dis"},{"key":"B21","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.nmd.2018.07.003","article-title":"Graves' disease and celiac disease in a patient with myotonic dystrophy type 2","volume":"28","author":"Damen","year":"2018","journal-title":"Neuromuscular Dis"},{"key":"B22","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.msard.2018.06.020","article-title":"White matter hyperintensities in myotonic dystrophy type 2: not always another expression of the disease","volume":"24","author":"Karatzikou","year":"2018","journal-title":"Mult Scler Relat Disord."},{"key":"B23","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.nmd.2018.07.014","article-title":"Self-diagnosis of a Triple Trouble","volume":"28","author":"Schoser","year":"2018","journal-title":"Neuromuscular Disorders"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2744","DOI":"10.1007\/s00415-020-10049-5","article-title":"Neuromyelitis optica and myotonic dystrophy type 2: a rare association with diagnostic implications","volume":"267","author":"Gelibter","year":"2020","journal-title":"J Neurol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1002\/dmrr.2486","article-title":"Steroid-induced diabetes: a clinical and molecular approach to understanding and treatment","volume":"30","author":"Hwang","year":"2014","journal-title":"Diabetes Metab Res Rev."},{"key":"B26","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1089\/jop.2006.0067","article-title":"The etiology of steroid cataract","volume":"23","author":"James","year":"2007","journal-title":"J Ocul Pharmacol Ther"},{"key":"B27","doi-asserted-by":"publisher","first-page":"243","DOI":"10.5114\/reum.2018.77976","article-title":"Antinuclear antibodies in healthy people and non-rheumatic diseases \u2013 diagnostic and clinical implications","volume":"56","author":"Grygiel-G\u00f3rniak","year":"2018","journal-title":"Reumatologia."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2011.11.024","article-title":"The X chromosome and the sex ratio of autoimmunity","volume":"11","author":"Selmi","year":"2012","journal-title":"Autoimmun Rev"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1086\/421528","article-title":"Insulin Receptor Splicing Alteration in Myotonic Dystrophy Type 2","volume":"74","author":"Savkur","year":"2004","journal-title":"Am J Hum Genet"},{"key":"B30","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/ng.543","article-title":"Multiple common variants for celiac disease influencing immune gene expression","volume":"42","author":"Dubois","year":"2010","journal-title":"Nat Genet"},{"key":"B31","doi-asserted-by":"publisher","first-page":"10746","DOI":"10.1073\/pnas.95.18.10746","article-title":"New susceptibility locus for rheumatoid arthritis suggested by a genome-wide linkage study","volume":"95","author":"Cornelis","year":"1998","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B32","doi-asserted-by":"publisher","first-page":"3617","DOI":"10.1098\/rspb.2011.1537","article-title":"The causes of epistasis","volume":"278","author":"de Visser","year":"2011","journal-title":"ProcBiol Sci."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1038\/s41431-020-0700-2","article-title":"Improved HLA-based prediction of coeliac disease identifies two novel genetic interactions","volume":"28","author":"Erlichster","year":"2020","journal-title":"Eur J Hum Genet"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.932883\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T11:36:53Z","timestamp":1658144213000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.932883\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,18]]},"references-count":33,"alternative-id":["10.3389\/fneur.2022.932883"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2022.932883","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,18]]},"article-number":"932883"}}